Navigation Links
IntelliCyt Introduces New System for Multiplexed Screening of Suspension Assays
Date:1/12/2013

Albuquerque, NM, (PRWEB) January 12, 2013

IntelliCyt Corporation, a provider of assay screening solutions for phenotypic drug discovery, antibody discovery and in vitro toxicity testing, today announced the introduction of their new iQue™ Screener. The new system is the latest addition to IntelliCyt’s platform of instrumentation, application-specific reagents, integrated multi-user analysis and informatics tools. The iQue Screener will be unveiled tomorrow at the Society for Laboratory Automation and Screening (SLAS) 2nd Annual Conference in Orlando, Florida.

“The iQue Screener is our next generation system, integrating IntelliCyt’s technology into an instrument that is ideal for the screening environment. Researchers can now evaluate compound effects on non-adherent cell lines, primary immune system cells and molecular interactions using cell or bead-based screening assays”, commented Terry Dunlay, CEO at IntelliCyt. “Laboratories will see a drastic reduction in time to final results and be able to generate higher quality and more reproducible data. Our early access customers have been very happy with the ease of use, workflow support and powerful data analysis capabilities the system provides.”

IntelliCyt’s screening systems for cell and bead-based assays are the first high-throughput, high-content bench top analyzers designed for rapid screening of cells and beads in suspension. Unlike other screening technologies that provide data on a per well basis, IntelliCyt’s technology provides information-rich data on a cell by cell basis in 96- and 384-well microplates. Micro-volume sample delivery combined with rapid sample processing and highly sensitive multiplexing capabilities let researchers in many fields screen large libraries at unprecedented speed and also drastically reduce costs.

About IntelliCyt Corporation

IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. For more information, please visit http://www.intellicyt.com.

Contact:
IntelliCyt Corporation
Michael Sjaastad, Director of Business Development
505-345-9075
MSjaastad(at)intellicyt(dot)com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10314119.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. iLuv Introduces a Range of Accessories to Enhance Apple’s Lightning Devices at 2013 CES
2. RURO Introduces the FreezerPro® ColdTrack RFID Kit
3. Zinman & Company Introduces Year-End Tax Review for Clients Using Virtual Controllership Services
4. White Mountain Process Introduces Squeal-less Mechanical Seal
5. AllCells Introduces Autoimmune Diseased Cells and Tissue Products
6. Vision Research Introduces the Newest Member Of the Phantom®- 1Mpx- v-Series Camera Family
7. JPSA Introduces Picosecond Laser Micromachining System
8. Profit Lifter for Pro Mold Removers: Molderizer Introduces Remediation Product Like No Other
9. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
10. NextGen introduces its first generation of animal biomarker products for development of brain disorder diagnostics
11. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... National Pharmaceutical Council (NPC) today announced that Ipsen Biopharmaceuticals, ... its newest member. David Cox , PhD, Vice ... ), will serve as his company,s representative on ... have Ipsen and Dr. Cox join NPC as members," ... their insights in helping us identify and address health ...
(Date:3/28/2017)... ... March 28, 2017 , ... LabKey and collaborator Just Biotherapeutics, ... solution, LabKey Biologics . Built in collaboration with Just and designed with ... provides drug research teams tools for biological entity registration, assay data integration, and ...
(Date:3/28/2017)... Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the ... from its phase 1/2 tendon repair study investigating the use ... a treatment for Achilles tendinosis. ... The clinical trial met its ... and showed no serious adverse events related to the study ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... to accelerating the fight against cancer, autoimmune disease and more through a single-cell ... single-cell metabolomics and proteomics analysis platform developed in the laboratory of Dr. ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/28/2017)... --  Acuant , a leading provider of data capture ... new and core technologies building upon the acquisition of ... desktop Acuant FRM TM facial recognition and match ... manual review of identity documents by accredited professionals. ... most accurate capture software to streamline workflows by securely ...
Breaking Biology News(10 mins):